What Does Novo Nordisk’s (NVO) Once A Week Insulin Mean For Investors?

Novo Nordisk A/S (NYSE:NVO) is one of the 8 Dirt Cheap Stocks to Buy With $1000 Right Now. On March 27, Novo Nordisk A/S (NYSE:NVO) said that the U.S. Food and Drug Administration approved Awiqli injection (700 units/mL), a once-weekly long-acting basal insulin for adults with type 2 diabetes. It is used along with exercise and diet to help control blood sugar levels. The company highlighted that this is the first and only basal insulin that needs to be taken once a week, offering patients a more flexible treatment option.

The approval is based on results from the  ONWARDS phase 3a program, which included about 2,680 adults with uncontrolled type 2 diabetes. In these studies, Awiqli was tested in combination with mealtime insulin or other common diabetes treatments such as oral drugs and  GLP-1 receptor agonists. The trials compared once-weekly Awiqli with daily basal insulin and showed that it effectively reduced HbA1c levels.

Earlier, on March 26, Hims & Hers Health announced that it started selling Novo Nordisk A/S (NYSE:NVO)’s GLP-1 drugs Wegovy (semaglutide) and Ozempic (semaglutide) for weight loss and type 2 diabetes. The launch follows a resolved dispute between the two companies, which now limits Hims & Hers Health’s ability to offer most compounded semaglutide versions.

Novo Nordisk A/S (NYSE:NVO) is involved in the manufacture, development, research, and distribution of pharmaceutical products. The company operates in the Rare Disease and Obesity & Diabetes Care segments. It was incorporated in 1923 and is based in Bagsvaerd, Denmark.

READ NEXT: 8 Best American Stocks to Buy and Hold in 2026 and 12 Best Mid Cap AI Stocks to Buy According to Hedge Funds.

Disclosure: None. Follow Insider Monkey on Google News.